Triple-negative breast cancer is a combative cancer type with a highly inflated histological
grade that leads to poor theragnostic value. Gene, protein, and receptor-specific targets …

Breast cancer is the most common malignancy and the second most common cause of
cancer-related mortality in women. Triple-negative breast cancers do not express estrogen …

Design of multifunctional nanoplatforms combined with ultrasound-targeted microbubble
destruction (UTMD) technology for enhanced tumor accumulation is feasible to solve the …

The immunosuppressive state in the tumor microenvironment (TME) of breast cancer makes
it difficult to treat with immunotherapy. Oncolytic viruses not only lyse tumor cells but also …

Triple-negative breast cancer (TNBC) surpasses other BC subtypes as the most challenging
to treat due to its lack of traditional BC biomarkers. Nearly 30% of TNBC patients express the …

Simple Summary Breast cancer is the most common cancer affecting women, and the
importance of NR function in breast cancer biology has been recognized since the turn of …

Simple Summary The literature aims to explore anti-androgenic particulars against luminal
androgen receptor-specific triple-negative breast cancer, thus providing a concise report on …

The last decade has witnessed the altered expression levels of long non-coding RNA HEIH
in different types of cancer. More than half of the HEIH studies in cancer have been …

Triple-negative breast cancers (HER2−, ER−, PR−) continue to present a unique treatment
challenge and carry unfavorable prognoses. The elucidation of novel therapeutic targets has …

Purpose Androgen receptor (AR) expression is absent in 40–90% of estrogen receptor (ER)-
negative breast cancers. The prognostic value of AR in ER-negative patients and …